ASH Annual Meeting

Dr. Michael Wang discusses ECHO long-term data, revealing that concurrent therapy for mantle cell lymphoma significantly outperforms sequential treatment.

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria as key indicators of patient survival.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results.

ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.

Matthew Matasar, MD, discusses real-world data on treatment options for diffuse large B-cell lymphoma.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated DLBCL patients, without rituximab.

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Dr Robert Orlowski highlights strategies to prevent infections in patients with multiple myeloma treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.

Explore the significance of MRD negativity in cancer prognosis and its implications for treatment strategies in community-based practices.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

New data reveals that the BPd treatment combination significantly improves outcomes in relapsed multiple myeloma, outperforming traditional therapies.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

The MonumenTAL-2 study reveals promising results for talquetamab and pomalidomide in treating relapsed/refractory multiple myeloma, showcasing high response rates.

Researchers explore the safety and efficacy of consolidating cevostamab with BCMA CAR T therapy for relapsed multiple myeloma, highlighting management protocols.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

KLN-1010 shows promising MRD-negative responses in relapsed/refractory multiple myeloma patients, highlighting its potential as a safe, off-the-shelf CAR T therapy.

The LimiTEC trial reveals that discontinuing teclistamab after 6-9 months yields comparable outcomes to continuous treatment in multiple myeloma patients.

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

Discover how a remote therapeutic monitoring system enhances patient care and streamlines clinic operations, reducing hospitalizations for hematologic malignancies.

A phase 1b/2 trial reveals MK-1045 shows manageable safety and promising efficacy in treating relapsed/refractory B-cell acute lymphoblastic leukemia.

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, enhancing outpatient care and reducing emergency visits.

The MANIFEST-2 trial reveals that pelabresib combined with ruxolitinib significantly improves outcomes for myelofibrosis patients compared to standard treatments.

New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.